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Purpose: To report the results of a correlation analysis of skin dose assessed by in vivo dosimetry and the incidence of acute 
toxicity. This is a phase 2 trial evaluating the feasibility of intraoperative radiotherapy (IORT) as a boost for breast cancer patients. 
Materials and Methods: Eligible patients were treated with IORT of 20 Gy followed by whole breast irradiation (WBI) of 46 
Gy. A total of 55 patients with a minimum follow-up of 1 month after WBI were evaluated. Optically stimulated luminescence 
dosimeter (OSLD) detected radiation dose delivered to the skin during IORT. Acute toxicity was recorded according to the Common 
Terminology Criteria for Adverse Events v4.0. Clinical parameters were correlated with seroma formation and maximum skin dose. 
Results: Median follow-up after IORT was 25.9 weeks (range, 12.7 to 50.3 weeks). Prior to WBI, only one patient developed acute 
toxicity. Following WBI, 30 patients experienced grade 1 skin toxicity and three patients had grade 2 skin toxicity. Skin dose during 
IORT exceeded 5 Gy in two patients: with grade 2 complications around the surgical scar in one patient who received 8.42 Gy. 
Breast volume on preoperative images (p = 0.001), ratio of applicator diameter and breast volume (p = 0.002), and distance between 
skin and tumor (p = 0.003) showed significant correlations with maximum skin dose.
Conclusions: IORT as a boost was well-tolerated among Korean women without severe acute complication. In vivo dosimetry 
with OSLD can help ensure safe delivery of IORT as a boost. 
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Introduction
Whole breast irradiation (WBI) followed by tumor bed boost 
is standard radiation treatment in patients with breast cancer 
undergoing breast-conserving surgery (BCS). Nevertheless, 
in selected patients with early breast cancer, partial breast 
irradiation (PBI) has shown acceptable local control rates 
with good cosmetic results [1]. Targeted intraoperative 
radiotherapy-A (TARGIT-A) trial used low energy X-rays (50 kV) 
generated from Intrabeam (Carl Zeiss Meditec AG, Oberkochen, 
Germany) for delivering PBI during BCS and reported non-
inferiority of intraoperative radiotherapy (IORT) compared to 
WBI using external beam radiation therapy (EBRT) in selected 
early breast cancer patients [2]. While American Society for 
Radiation Oncology (ASTRO) consensus guidelines recommend 
accelerated PBI for selected patients with early breast cancer 
[3], the feasibility of applying IORT as a boost to WBI in high-
risk patients remains to be demonstrated. The use of IORT 
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as boost has been examined in retrospective studies [4,5] 
and a randomized comparison of these techniques with WBI 
followed by EBRT boost is currently underway in the TARGIT-B 
trial. 
IORT delivers high dose to the tumor cavity and spares 
normal breast tissue; however, the radiation dose delivered 
to overlying skin and association with toxicity require 
close attention. Acute and late complications of IORT using 
Intrabeam include pain, seroma, wound infection, fibrosis, 
hyperpigmentation, edema of the breast, and ulceration 
[6,7]. One limitation of IORT is the lack of image-guided 
pretreatment plans, without which operators are unable to 
anticipate the radiation dose delivered to adjacent organs such 
as the overlying skin. Therefore, methods to assess radiation 
dose to the skin during IORT delivery (in vivo dosimetry) can 
be helpful in predicting the risk of developing skin toxicities 
and establishing proper inclusion criteria for future IORT 
applications. Since applying IORT as a boost has the potential 
to result in increased skin toxicity compared with IORT 
alone, additional safety evaluation is required for Korean 
patients whose breast volumes tend to be smaller than those 
of Western population. Since August 2014, a phase 2 trial 
investigating safety and feasibility of IORT used as a boost 
treatment in Korean patients requiring BCS has been underway 
at our institution. In the present report, we present the results 
of in vivo dosimetry and the correlation analysis of the factors 
associated with increased skin dose and acute toxicity.
Materials and Methods
1. Study endpoints and eligibility
The primary endpoint was to provide an independent 
assessment of the delivered dose and consistency of the IORT 
technique through optically stimulated luminescent dosimeter 
(OSLD)-based in vivo dosimetry. The secondary endpoint was 
to determine clinical factors associated with increased risk 
of delivering a higher skin dose than intended. The phase 2 
trial allowed enrollment of patients with histologically proven 
breast cancer undergoing BCS, aged 20 years or older, and with 
maximum tumor size less than 5 cm and Eastern Cooperative 
Oncology Group (ECOG) performance status of 1 or 2, but 
excluded patients who received neoadjuvant chemotherapy 
prior to BCS, or who required surgery for bilateral breast 
cancer. The study protocol conforms to the ethical guidelines 
of the 1975 Declaration of Helsinki, and was approved by 
Gangnam Severance Hospital Institutional Review Board (No. 
3-2013-0299). All subjects provided informed consent prior to 
enrollment; all patients presented at a multidisciplinary tumor 
board at our institution.
2. IORT procedure
Two experienced surgeons were in charge of BCS. During BCS, 
a single fraction of 20 Gy was prescribed to the surface of the 
tumor cavity using the mobile 50-kV X-ray source (Intrabeam) 
(Fig. 1). The X-ray source was attached to the robotic arm 
which maintained the stability of the source throughout 
the whole process. Isotropy and the output of the unit were 
verified; the pre-IORT calibration process required by the 
system was performed prior to each treatment. Immediately 
after excision of the tumor, frozen sections were sent to the 
Department of Pathology for analysis to prevent positive 
resection margins after BCS. Re-excision was performed in 
cases of positive resection margins on frozen section analysis 
prior to IORT. A spherical applicator with an appropriate 
diameter (ranging from 1.5 to 5.0 cm in 0.5 cm increments) 
was selected according to the size of the tumor cavity, and the 
applicator was attached over the probe of the X-ray source. 
With a sterile sheath draped over the IORT device to prevent 
contamination, the spherical applicator was placed inside the 
tumor cavity, and a purse-string suture was used to pull the 
walls of the tumor cavity tightly against the applicator surface. 
The edges of the skin incision were everted so any part of skin 
was at least 1 cm away from the applicator surface to avoid 
excessive radiation exposure. When the skin-to-tumor distance 
Fig. 1. Intraoperative radiotherapy device.
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was less than 1 cm, the portion of the skin overlying the tumor 
was excised to prevent suboptimal radiation dose delivery to 
the high risk area due to skin-edge eversion. Actual beam-
on time after radiation site shielding was 20 to 30 minutes 
depending on applicator diameter. The surface of the tumor 
cavity received 20 Gy, while the radiation dose was attenuated 
to approximately 5 Gy at 1 cm depth. IORT was followed, with 
or without chemotherapy, by WBI of 46 Gy in 23 fractions. 
3. In vivo dosimetry procedure
The OSLD used was InLight nanoDots (Landauer Inc., Glenwood, 
IL, USA) which has a 5 mm diameter with thickness of 0.2 mm 
protected in a plastic casing. For each IORT measurement, 8 
OSLD chips were annealed and attached to the skin, at 5 mm 
and 15 mm from the skin edge in the superior, inferior, medial 
and lateral locations (Fig. 2). After IORT, an InLight microStar 
reader (Landauer Inc.) which utilizes a photomultiplier tube 
(PMT) to collect the luminescence of the OSLD was used to 
determine the results of in vivo dosimetry. Each OSLD chip 
underwent measurements 3 times in the microStar reader; the 
average PMT count was recorded.
4. Toxicity evaluation and breast volume measurement
The Common Terminology Criteria for Adverse Events v4.0 was 
used for toxicity assessment. Findings such as wound infection, 
edema, erythema and palpable seroma were documented 1 
week and 1 month after IORT, at the end of WBI, and 1 month 
after WBI. Volumes of aspirated seroma were also documented. 
The ipsilateral breast of each patient on preoperative chest 
computed tomography images in supine position and breast 
magnetic resonance imaging (MRI) images in prone position 
was contoured according to the Radiation Therapy Oncology 
Group (RTOG) Breast Cancer Atlas for Radiation Therapy 
Planning. MIMVISTA 6.3.3. (MIM Software Inc., Cleveland, OH, 
USA) was used for contouring and calculating the preoperative 
breast volume of each patient on both imaging modalities.
5. Statistical analysis
Variables correlated with the maximum skin dose during IORT 
were determined using linear regression analysis; factors 
associated with seroma requiring aspiration 1 month after 
IORT were evaluated using logistic regression analysis. These 
variables included applicator diameter, skin-to-tumor distance 
in preoperative images, maximum tumor diameter, breast 
volume, volume of hemi-breast containing the tumor, ratio of 
applicator diameter and breast volume, and ratio of applicator 
volume and breast volume. The ratio of applicator diameter 
and breast volume was calculated as
Applicator diameter (cm)
Breast volume (mL)/1,000
and the ratio of applicator volume and breast volume was 
calculated as
Applicator volume (mL)
Breast volume (mL)/1,000 .
The p-values of <0.05 were considered significant; all 
statistical analyses were performed using IBM SPSS ver. 20.0 
(SPSS Inc., Chicago, IL, USA).
Results
1. Patients and treatment characteristics
From August 2014 until August 2015, IORT was considered in 
124 patients; 82 patients actually underwent IORT and were 
enrolled in the phase 2 study. Among the 42 patients who 
did not undergo IORT, the reasons of IORT cancellation were 
either preoperative decisions in multidisciplinary conference, 
including presence of a huge primary mass or multicentric 
tumor nodules (n = 4); neoadjuvant chemotherapy (n = 3); 
definitive axillary, supraclavicular, or internal mammary lymph 
node metastasis (n = 3); and tumor close to the skin (n = 
9); and intraoperative decisions including persistent positive 
resection margins (n = 9), conversion to total mastectomy (n 
= 8), and shape of tumor cavity unsuitable for IORT (n = 6). 
Among the 82 patients treated with IORT, 55 patients who 
underwent a minimum follow-up period of 1 month after WBI 
were included in the analysis. Follow-up after IORT ranged 
from 12.7 weeks to 50.3 weeks with a median follow-up of 
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Fig. 2. (A) Schematic arrangement of optically stimulated 
luminescent dosimeter (OSLD) and (B) example of OSLD 
arrangement in operating room.
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25.9 weeks. The median patient age was 52 years (range, 32 
to 69 years), invasive ductal carcinoma was the most common 
type (69.1%), and tumors were most frequently located in the 
upper quadrant (87.3%). T stages according to the American 
Joint Committee on Cancer (AJCC) 7th edition were Tis in 7 
patients, T1 in 40 patients and T2 in 8 patients; 4 patients were 
staged with N1 disease after operation with a single positive 
axillary lymph node. No patient had positive margins in frozen 
sections, but permanent pathology revealed positive margins 
in 3 patients. In these 3 patients, surgical re-excision was 
recommended; however, the patients refused. Sixteen patients 
received adjuvant chemotherapy and 37 patients received 
hormonal therapy. The median interval between IORT and of 
the initiation of EBRT was 5.7 weeks (range, 4.4 to 29.1 weeks). 
Patient, tumor, and treatment characteristics are summarized 
in Table 1. The median beam-on time was 18.15 minutes (range, 
17.25 to 26.27 minutes); the diameters of applicators used 
were 2.5 cm (n = 3), 3.0 cm (n = 19), 3.5 cm (n = 28), and 4.0 
cm (n = 5). 
2. Toxicity
IORT followed by WBI was well tolerated. Although one patient 
experienced wound infection and required wound revision 
after BCS and IORT, no other patient experienced acute 
complications between IORT and the 1-month follow-up. 
Adverse skin reactions following WBI were observed in 33 (60%) 
patients, among whom 3 (5.5%) experienced grade 2 toxicity. 
More severe toxicity was not reported (Table 2). Fifty patients 
with seroma required aspiration at 1 week after IORT, 28 at 1 
month after IORT, and 10 immediately after WBI. 
 
3. In vivo dosimetry
At 5 mm from the skin edge, a maximum dose of 8.42 Gy was 
recorded, with a median dose of 1.76 Gy (range, 0.54 to 8.42 
Gy) and a mean dose of 1.91 Gy. At 15 mm from the skin edge, 
a maximum dose of 6.58 Gy was recorded, with a median 
dose of 1.28 Gy (range, 0.44 to 6.58 Gy) and a mean dose of 
1.41 Gy. Maximum dose recorded at 5 mm from skin edge was 
higher than maximum dose recorded at 15 mm from skin edge 
in every patient. As 20 Gy was prescribed to the applicator 
surface and the minimum applicator-to-skin distance was 
maintained at more than 1 cm, the expected maximum 
skin dose was approximately 5 Gy. In 2 patients, however, 
maximum doses of 5.33 Gy and 8.42 Gy were recorded; the 
breast volumes of these patients were 309 mL and 289 mL, 
respectively. The breast volume/applicator diameter ratios were 
8.09 and 10.38. In both cases, the tumor was located close to 
the breast margin and the distance between skin and tumor, 
calculated from the dose distribution curve, was 1.3 cm for 5.33 
Gy and 0.6 cm for 8.42. The patient with maximum dose of 8.42 
Gy at 5 mm from the skin edge experienced grade 2 erythema 
at the spot where the maximum dose was measured (Fig. 3), 
although no skin reaction had been reported prior to WBI. 
4. Risk factor analysis
The median breast volume was 567.8 mL (range, 157.2 to 
1,634.1 mL) on MRI images in prone position and 511.4 mL 
(range, 230.1 to 1,494.8 mL) on CT images in supine position. 
The median volume of the tumor-bearing hemi-breast was 
287.1 mL (range, 104.1 to 1,015.4 mL) on MRI and 287.2 mL 
(range, 112.3 to 969.2 mL) on CT. In 6 (11%) patients, the tumor 
Table 1. Patient and treatment characteristics
Characteristic Value
Age (yr)
Pathology
 DCIS
 IDC
 Other
Site
 Left upper
 Left lower
 Right upper
 Right lower
Tumor size (cm)
 <1
 >1
 Unmeasurable
T stage
 Tis
 T1
 T2
N stage
 N0
 N1
Number of positive lymph nodes
 0
 1
Resection margin of permanent section
 Positive
 Negative
Adjuvant chemotherapy
 AC (doxorubicin/cyclophosphamide)
 AC + paclitaxel
 No
Hormone therapy
 Yes
  No
Interval between IORT & EBRT (mo)
  52 (32–79)
  7 (12.7)
  38 (69.1)
  10 (18.1)
  25 (45.5)
  4 (7.2)
  23 (41.8)
  3 (5.5)
  1.4 (0.1–2.7)
  17 (30.9)
  37 (67.3)
  1 (1.8)
  7 (12.7)
  40 (72.7)
  8 (14.5)
  51 (92.7)
  4 (7.3)
  51 (92.7)
  4 (7.3)
  3 (5.5)
  52 (94.5)
  15 (27.2)
  1 (1.9)
  39 (70.9)
  37 (67.3)
  18 (32.7)
  5.7 (4.4–29.1)
Values are presented as median (range) or number (%).
DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma; 
IORT, intraoperative radiotherapy; EBRT, external beam radiation 
therapy.
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was located less than 1 cm from adjacent skin. Among 28 
patients who presented with wound seroma needing aspiration 
1 month after IORT, median and mean volume of seroma were 
1.5 mL (range, 1.0 to 84.0 mL) and 5.5 mL. According to our 
institution’s criteria, 15 patients presented with considerable 
volume of seroma (>5 mL). Analysis of factors associated with 
a considerable volume of seroma (>5 mL) 1 month after IORT 
revealed that applicator diameter was a significant factor in 
both univariate (p = 0.042) and multivariate analyses (p = 
0.049) (Table 3). Linear regression analysis showed a significant 
correlation between maximum skin dose and preoperative 
breast volume (p < 0.001), distance between skin and tumor 
on preoperative images (p = 0.001), and ratio of breast volume 
and applicator diameter (p < 0.001). Table 4 summarizes the 
results of linear regression analysis of factors associated with 
skin dose.  
5. Receiver operating characteristic (ROC) analysis
Thirty-eight patients had a maximum skin dose larger than 2 
Gy, while 17 patients had a maximum skin dose larger than 3 
Gy. Median and mean skin dose were 2.26 Gy (range, 1.03 to 
8.42 Gy) and 2.68 Gy. The inflection point of the maximum skin 
dose among the 55 patients was located between 2 Gy and 3 
Gy. Therefore, patients recording maximum skin dose higher 
than 3 Gy can be regarded as larger than average group. ROC 
Table 2. Toxicity (any grade) (n = 55)
Skin toxicity 1 week after IORT 1 month after IORT Immediately after WBI 1 month after WBI
Erythema (grade 1)
Erythema (grade 2)
Wound infection
Breast edema
Seroma needing aspiration
Seroma (mL)
 0 (0)
 0 (0)
 1 (1.8)
 0 (0)
 50 (90.9)
 15.4 (0–102)
 0 (0)
 0 (0)
 0 (0)
 0 (0)
 28 (50.9)
 5.5 (0–84)
 30 (54.5)
 3 (5.4)
 0 (0)
 0 (0)
 10 (18.2)
 1.6 (0–22)
 2 (3.6)
 0 (0)
 0 (0)
 0 (0)
N/A
N/A
Values are presented as number (%) or median (range).
Table 3. Toxicity (seroma > 5 mL)
Univariate analysis Multivariate analysis
95% CI p-value 95% CI p-value
Age
Applicator diameter (cm)
 ≤3.5
 >3.5
Skin tumor distance
Maximum diameter on MRI (cm)
Diameter of applicator/volume of breast
Maximum skin dose
 0.966–1.120
 1.097–124.835
 0.601–3.371
 0.652–4.083
 0.657–1.151
 0.448–1.492
0.295
0.042
0.422
0.296
0.329
0.512
 0.899–1.083
 1.014–154.325
 0.472–4.627
 0.562–5.713
 0.615–1.299
 0.476–2.205
0.781
0.049
0.503
0.324
0.557
0.950
CI, confidence interval; MRI, magnetic resonance imaging.
Fig. 3. Patient with maximum dose of 8.42 Gy developed 
skin toxicity during external beam radiation therapy (EBRT). 
Photographs were taken (A) after 14 fractions of EBRT and (B) 
immediately after the completion of EBRT.   
A
B
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analysis was performed to distinguish useful parameters for 
predicting a maximum skin dose larger than 3 Gy. Among the 
risk factors mentioned above, the ratio of applicator diameter 
and breast volume was the best parameter for anticipating 
skin dose greater than 3 Gy. The area under the curve (AUC) 
was 0.820, and a threshold value of 7 resulted in the optimal 
sensitivity and specificity, 82.4% and 73.4%, respectively. The 
AUC of breast volume and the distance between skin and 
tumor were 0.165 and 0.267.
Discussion and Conclusion
IORT boost is known to offer several advantages over external 
beam boost in patients with breast cancer undergoing 
BCS. Immediate initiation of radiation after tumor removal 
may reduce the chances of tumor cell repopulation; direct 
placement of the applicator in the tumor cavity could reduce 
the possibility of targeting error that may occur due to daily 
setup errors and vague identification of the tumor bed on CT 
images acquired several weeks after surgery. Furthermore, dose 
distribution with steep dose fall-off allows increased dose to 
the tumor bed while reducing radiation to adjacent structures 
including skin and other organs such as the heart and lungs 
[8,9].
Although a few IORT-alone trials reported lower toxicity and 
survival rates comparable to those of WBI in low-risk patients 
with early breast cancer [2,7], higher local recurrence rates and 
lack of long-term follow-up of those studies prevent clinicians 
from moving to a single session of IORT from WBI [10-12]. 
On the other hand, IORT could be a method of delivering a 
boost dose in combination with WBI; its feasibility as a boost 
treatment has been examined retrospectively. Vaidya et al. 
[13] reported that lumpectomy and TARGIT boost combined 
with WBI resulted in superior local tumor control compared 
to the results of the European Organization for Research and 
Treatment of Cancer (EORTC) boost trial or the Standardization 
of Breast Radiotherapy-B (START-B) trial. In addition, a single 
center experience at University Medical Centre Mannheim 
using low-kV X-ray IORT as a boost resulted in 5-year overall 
survival of 91.3% with 5-year local recurrence-free survival of 
97.0% [6]. An ongoing trial, TARGIT-B, is comparing IORT boost 
and EBRT boost in high-risk patients. 
Intrabeam IORT requires inserting a spherical applicator 
in the tumor cavity and delivering a high radiation dose in 
a single fraction; thus, the toxicity risk is likely dependent 
on geometric variations such as applicator diameter, tumor 
location, and breast volume. However, no published studies 
clearly indicate exclusion criteria based on such geometric 
variables in the application of Intrabeam IORT.
As the breast volume of East Asian women is generally 
smaller than that of Western patients [14], it is imperative 
that the risk factors associated with increased toxicity are 
evaluated prior to the wide use of Intrabeam IORT in Korea. We 
conducted an in vivo dosimetry study for patients undergoing 
Intrabeam IORT followed by WBI, and correlated geometrical 
variables of the breast with increased maximum skin dose.
Some researchers regard seroma as a natural consequence 
of PBI rather than a complication [15] and have concluded 
that IORT is not associated with increased volume of seroma 
requiring treatment [16]. Even though other factors than IORT 
boost, such as body mass index and age could contribute to 
the formation of seroma [5], careful observation is necessary 
after IORT, as wound seroma needing aspiration was reported 
more frequently in patients undergoing IORT than in patients 
undergoing EBRT in the TARGIT-A trial as well as in the 
report by Kraus-Tiefenbacher et al., in which 48% of patients 
had measurable seroma 1 month after IORT boost [2,5]. 
Although neither of the study provided the optimum value for 
evaluation of seroma formation, we used 5 mL as a criteria 
considering mean volume of seroma 1 month after IORT boost 
was 5.5 mL. The present study showed that the applicator 
diameter was an independent predictor of significant seroma 
formation; however, whether or not the volume of seroma also 
depends on the high-dose irradiation during IORT remains to 
be determined. 
Cosmetic outcome is an important factor that should be 
considered in patients with breast cancer. Cracco et al. [17] 
reported comparable cosmetic outcomes between 81 patients 
treated with IORT and 105 patients treated with traditional 
EBRT. Further follow-up is required to assess the rate of late 
complications and cosmetic outcomes in Korean patients with 
Table 4. Factors associated with skin dose
R2 p-value
Skin-tumor distance
Breast volume
 CT
 MRI
Diameter of applicator/volume of breast
 CT
 MRI
Volume of applicator/volume of breast
 CT
 MRI
0.184
0.254
0.274
0.245
0.210
0.060
0.067
0.001
<0.001
<0.001
<0.001
<0.001
0.072
0.060
CT, computed tomography; MRI, magnetic resonance imaging.
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breast cancer undergoing IORT boost followed by WBI. 
The novelty of this study is in determining selection criteria 
for high-risk patients using in vivo dosimetry during IORT. 
Recently, OSLD has been widely used in measuring multiple 
radiation dose types, such as heavy ion beams, photons, 
electrons, and protons. Sharma and Jursinic [18] successfully 
used OSLD in surface dose measurement for high dose rate 
(HDR) brachytherapy with minimal uncertainty. The data 
acquired from in vivo dosimetry were useful in determining 
factors related to higher skin dose, which may increase the 
risk of acute and late skin reactions. As we have illustrated, 2 
patients in the present study received skin doses higher than 
5 Gy despite efforts to keep adjacent skin at least 1 cm away 
from the applicator. Therefore, patients who have similar 
characteristics to these 2 patients, such as relatively small 
breast volume, tumor location close to the breast margin, and 
small skin-to-tumor distance, require careful attention. In the 
present study, preoperative breast volume, distance between 
skin and tumor on preoperative images, and ratio of breast 
volume and applicator diameter were found to be significant 
factors associated with higher skin dose; these factors must 
be considered before performing IORT. We are now using these 
pre-selection criteria in order to exclude patients with a high 
risk of skin toxicity at our institution.
The safety of IORT alone in the Asian population was 
reported by Sawaki et al. [19], who evaluated the toxicity 
of IORT with 21 Gy in 5 Japanese patients with early breast 
cancer. The results of boost IORT in Asian patients are minimal; 
no institution has yet performed IORT for patients with breast 
cancer in Korea. 
In conclusion, IORT boost was well tolerated among Korean 
patients with breast cancer, without severe acute toxicity. The 
data acquired in this study using in vivo dosimetry could be 
useful in selecting appropriate candidates for IORT boost in 
the future. The results of the phase 2 trial and the assessment 
of late toxicity will follow.
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